21/05/2026
MRI has long helped clinicians see anatomy. Imaginostics is working to help it measure biology.
The company is advancing a new approach to MRI through quantitative vascular imaging and AI-powered analytics — designed to transform scans into measurable clinical insight.
At the center of the platform are ImagiView™ and ImagiSight™, technologies built to support earlier disease detection, longitudinal monitoring, and more personalized treatment decisions across neurology, cardiovascular disease, oncology, and beyond.
“Our vision is to build a future where MRI does not simply show anatomy, but reveals measurable vascular biology that can guide better decisions throughout a patient’s life,” said Dr. Codi Amir Gharagouzloo, Ph.D and Valerie Gharagouzloo, Cofounders of Imaginostics.
Read the full article for all details 👇
https://med-tech.world/news/imaginostics-new-data-layer-mri/
Up Next:
✈️MedTech World Asia 2026
📅26–28 Aug 2026 | Hong Kong
🎟️Secure your pass: https://tickets.med-tech.world/medtechworld-asia-2026
Imaginostics is advancing MRI through quantitative vascular imaging and AI-powered analytics, aiming to deliver earlier diagnosis and more precise clinical insight.